SecBot SecBot
8-K ·Filed Nov 12, 2026

EQ

Equillium, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed9d 14h ago SEC0001193125-26-458379
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor for EQ504 Phase 1 proof-of-mechanism data expected in Q2 2027, which will inform the planned proof-of-concept study in ulcerative colitis. The $20M financing triggered by first patient dosing removes near-term funding risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drug in focus

EQ drug pipeline →

EQ504

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
Unknown — the drug is in Phase 1 healthy-volunteer testing. If successful through Phase 2 and Phase 3, potential approval would be several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchThe next hard catalyst is topline Phase 1 proof-of-mechanism data in Q2 2027 (~6 months from now). Positive data showing AhR target engagement and a clean safety profile in healthy volunteers would validate the mechanism and support advancement into a Phase 2 proof-of-concept study in ulcerative colitis patients in H2 2027. Negative safety signals or failure to demonstrate target engagement would severely damage the thesis for a company now entirely dependent on EQ504 after its prior lead failed Phase 3.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.29
T+0 close · Nov 12, 2026 · via day close
Latest settled
−17.83%
T+5 · $1.06
Vs SPY
−9.27%
α at T+5
Next horizon
T+20
in 22d
  1. T+0 · Nov 13 $1.29entry
  2. T+1 · 6d ago −10.85%α −8.94% · $1.15
  3. T+5 · 2d ago −17.83%α −9.27% · $1.06
  4. T+20 · in 22d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The key event is the initiation of a Phase 1 trial for lead candidate EQ504, with proof-of-mechanism data expected in Q2 2027, and a $20M milestone financing closed in October 2026, extending cash runway into 2029.

Key Facts

  • First participant dosed in Phase 1 clinical trial of EQ504 in October 2026; proof-of-mechanism data expected Q2 2027
  • Closed second tranche of August 2025 private placement for $20M gross proceeds on October 26, 2026
  • Cash and cash equivalents $53.3M as of September 30, 2026; pro forma $72.0M including October financing
  • Cash runway expected into 2029
  • R&D expenses $2.5M in Q3 2026 vs $1.3M in Q3 2025; G&A $2.6M vs $3.3M

Financial Impact

Net loss of $4.6M in Q3 2026; cash position $53.3M ($72.0M pro forma); $20M milestone financing closed in October 2026

cashnet lossR&D expenses

Risk Factors

  • Clinical-stage biotech with no approved products; EQ504 Phase 1 data may not support advancement
  • Net loss widened year-over-year as R&D spending increased for EQ504 development
  • Dependence on successful clinical development of single lead candidate EQ504

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-458379
Document: eq-ex99_1.htm0001193125-26-458379
Document: 0001193125-26-458379-index-headers.html0001193125-26-458379
Document: 0001193125-26-458379-index.html0001193125-26-458379
Document: 0001193125-26-458379.txt0001193125-26-458379
8-K Data (Synthetic)0001193125-26-458379

Track record

20 reports on EQ

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +20.40% at T+60 after the Jun 5, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 20, 20262d ago EFFECT Neutral 4/10 Entry $1.12 Now $1.06 −5.36% settles Nov 23
  2. Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.21 to $1.10 Now $1.06 −12.40% ▼ −9.09% −8.79% vs SPY
  3. Nov 13, 20268d ago SC 13G/A Neutral 2/10 Entry $1.15 to $1.21 Now $1.06 −7.83% ▲ +5.22% +6.23% vs SPY
  4. Nov 12, 20269d ago S-3 Neutral 4/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
  5. Nov 12, 20269d ago 8-K Neutral 5/10 Viewing Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
  6. Nov 12, 20269d ago SC 13G/A Neutral 2/10 Entry $1.32 to $1.29 Now $1.06 −19.70% ▼ −2.27% −1.91% vs SPY
  7. Nov 4, 202617d ago SC 13G/A Neutral 2/10 Entry $1.40 to $1.33 Now $1.06 −24.29% ▼ −5.00% −0.59% vs SPY
  8. Oct 26, 202626d ago 8-K Bearish 6/10 Entry $1.36 to $1.42 Now $1.06 +22.06% ▼ −4.41% −4.07% vs SPY
  9. Oct 26, 202626d ago Press Release Neutral 4/10 Entry $1.25 to $1.36 Now $1.06 −15.20% ▲ +8.80% +8.24% vs SPY
  10. Oct 5, 20266w ago 8-K Neutral 3/10 Entry $1.42 to $1.39 Now $1.06 −25.35% ▼ −2.11% −1.87% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens Mon (26h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026